RT Journal Article
SR Electronic
T1 Contrast-enhanced 18F-FDG PET/CT in preoperative staging of pancreatic cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1747
OP 1747
VO 50
IS supplement 2
A1 Koranda, Pavel
A1 Mysliveček, Miroslav
A1 Havlik, Roman
A1 Kysucan, Jiri
A1 Buriankova, Eva
A1 Formanek, Radim
YR 2009
UL http://jnm.snmjournals.org/content/50/supplement_2/1747.abstract
AB 1747 Objectives Prognosis of patients (pts) with pancreatic carcinoma is poor. Surgery is the only effective therapy and preoperative staging is important step in the decision concerning an operability. The aim of the study was to assess the reliability of contrast-enhanced 18F-FDG PET/CT in the preoperative staging of pancreatic tumors. Methods A total of 80 pts with suspicion of pancreatic carcinoma or with CT diagnosed tumors underwent contrast-enhanced multislice 18F-FDG PET/CT. Malignancy was confirmed subsequently in 58 pts using intraoperative findings, histology, follow-up CT or clinical investigation as reference standards. Results Contrast-enhanced 18F-FDG PET/CT detected pancreatic carcinoma correctly in 51 pts, PET/ CT findings were false negative (FN) in 7 pts, false positive (FP) in 2 pts (sens. 88%, spec. 91%, accur. 89%). Reliability of N and M staging was evaluated in the subgroup of 49 pts which underwent surgical exploration. Lymph node involvement (19 pts) was detected using PET/CT in 13 pts, PET/CT was FN in 6 pts and FP 1 pts (sens. 68%, spec. 97%, accur. 86%). Distant metastases (18 pts.) were revealed using PET/CT in 10 pts, PET/CT was FN in 8 pts and FP in 1 pts (sens. 56%, spec. 97%, accur. 82%). In accordance with PET/CT results, 19 pts were judged to have not operable disease. Conclusions Contrast-enhanced 18F-FDG PET/CT appears to be an attractive staging tool for pancreatic cancer, although the N and M staging sensitivity values are lower than levels of specificity. It help to omit a futile surgery in patients with advanced disease.